NICE recommends Celgene ’s pancreatic cancer treatment abraxane for NHS use
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Celgene ’s nab-paclitaxel as a life-extending treatment for patients with progressive pancreatic cancer that has progressed. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news
Were NHS chiefs right to deny pancreatic cancer drug?
The news in late 2015 that abraxane was being rejected by NICE on cost grounds was met with anger by patient groups as some people had survived years when they had been given months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2017 Category: Consumer Health News Source Type: news
Halozyme Therapeutics reports positive top-line results from HALO 202 study of PEGPH20
US-based biotechnology company Halozyme Therapeutics has reported positive topline results from a combined analysis of two stages of its Phase II HALO 202 study of PEGPH20 in combination with abraxane and gemcitabine to treat pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - January 6, 2017 Category: Pharmaceuticals Source Type: news
Glenmark, Particle Sciences to develop generic cancer drug
The partnership will develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 19, 2016 Category: Pharmaceuticals Source Type: news
Allergan Confirms Generic Abraxane(R) Patent Challenge
DUBLIN, March 17, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) ... Biopharmaceuticals, Generics, FDAAllergan, Abraxane, Paclitaxel (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 17, 2016 Category: Pharmaceuticals Source Type: news
Halozyme begins dosing in Phase III trial of PEGPH20 combination to treat pancreatic cancer
US-based Halozyme Therapeutics has begun a Phase III clinical trial (Halo-301) of its investigational drug, PEGPH20, in combination with Abraxane (nab-paclitaxel) and gemcitabine for previously untreated metastatic pancreatic cancer patients. (Source: Drug Development Technology)
Source: Drug Development Technology - March 17, 2016 Category: Pharmaceuticals Source Type: news
NICE approves idelalisib and tolvaptan, not Abraxane
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2015 Category: Drugs & Pharmacology Source Type: news
Bothell biotech OncoGenex stock drops after failed pancreatic cancer trial
The negative results of a pancreatic cancer clinical trial released this morning had a chilling effect on one Puget Sound-area biotech company's stock.
Bothell-based OncoGenex Pharmaceuticals (Nasdaq: OGXI) this morning reported that a combination drug therapy did not succeed at treating pancreatic cancer in a Phase 2 clinical trial.
In the trial, the company combined OncoGenex's drug apatorsen with Celgene's drug Abraxane and a chemotherapy drug called gemcitabine (two drugs that are already approved… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 23, 2015 Category: Biotechnology Authors: Annie Zak Source Type: news
Pancreatic cancer patients denied life-extending drug by spending watchdog
The health spending watchdog has refused to fund the pancreatic abraxane despite evidence that it can double life expectancy (Source: Telegraph Health)
Source: Telegraph Health - September 16, 2015 Category: Consumer Health News Tags: pancreatic cancer pancreas symptims nice drugs treatments funding decision Source Type: news
Molecular tinkering doubles cancer drug's efficacy
(Duke University) Researchers at Duke University have molecularly repackaged a widely used cancer drug called paclitaxel, more than doubling its effectiveness at destroying tumors than the current gold-standard pharmaceutical, Abraxane. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2015 Category: Global & Universal Source Type: news
Nanotechnology platform shows promise for treating pancreatic cancer
Scientists at UCLA’s California NanoSystems Institute and Jonsson Comprehensive Cancer Center have combined their nanotechnology expertise to create a new treatment that may solve some of the problems of using chemotherapy to treat pancreatic cancer.
The study, published online in the journal ACS Nano, describes successful experiments to combine two drugs within a specially designed mesoporous silica nanoparticle that looks like a glass bubble. The drugs work together to shrink human pancreas tumors in mice as successfully as the current standard treatment, but at one twelfth the dosage. This lower dosage could reduce b...
Source: UCLA Newsroom: Health Sciences - March 23, 2015 Category: Universities & Medical Training Source Type: news
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
HONG KONG, March 18, 2015 -- (Healthcare Sales & Marketing Network) -- Celgene announced today that a new treatment option for late-stage pancreatic cancer is now available for use in Hong Kong. Approved by the Department of Health, Abraxane® (paclita... Biopharmaceuticals, Oncology, RegulatoryCelgene, Abraxane, paclitaxel, pancreatic cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2015 Category: Pharmaceuticals Source Type: news
EC grants approval for Celgene’s Abraxane to treat NSCLC
The European Commission (EC) has granted approval for Celgene International Sàrl's Abraxane (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin as a first-line treatment of non-small cell lung can… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 4, 2015 Category: Pharmaceuticals Source Type: news
Patients won't get vital pancreatic cancer drug that can extend life on the NHS
Hundreds of patients with advanced disease will be denied Abraxane, which extends life by two months when there are virtually no other options after experts decided the drug was not cost effective enough. (Source: the Mail online | Health)
Source: the Mail online | Health - December 30, 2014 Category: Consumer Health News Source Type: news
Specialised Therapeutics Australia To Increase Pancreatic Cancer Treatment Cost
Specialised Therapeutics Australia could not come to an agreement with the Australian government on the price of Abraxane, a drug for pancreatic cancer. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 28, 2014 Category: Pharmaceuticals Source Type: news
